Table 2.

Data on pamidronate treatment, MRI response, MRI confirmed CRMO relapse, and follow-up

IVP dosing frequency
One day monthly (n)	6/9
Three day cycle every 3 months (n)	3/9
Cumulative dose of pamidronate in mg/kg/year*	5.0 (4.5–9.5)
Time to > 90% MRI signal resolution after initial treatment (m)*	6.0 (2–12)
Number of IVP cycles required for > 90% MRI signal resolution*	5 (2–10)
Number of patients with clinical resolution of adjacent soft tissue swelling	5/5
Side effects from IVP
Myalgia and fever with first dose (n)	4/9
Osteonecrosis of the jaw (n)	0/9
Duration of follow-up after first IVP (m)*	31.4 (24–54)
Number of patients who relapsed	4/9
Time from first IVP to relapse (m)*	12.3 (12–18)
Time to >90% MRI signal resolution after repeat IVP treatment for CRMO relapse (m)	2 (for all patients)
Extra-osseus manifestations during follow-up
Psoriasis/palmoplantar pustulosis/acne	0/9; 0/9; 1/9
Synovitis/inflammatory bowel disease	0/9; 0/9

*Data presented as median (range).

MRI = magnetic resonance imaging.

IVP = intravenous pamidronate treatment.

n = number of patients.

m = months.